CPSA Portal will be unavailable from Dec. 13 – 15 due to a scheduled outage. Please complete your annual renewal and/or access documents and other applications outside of these dates. We apologize for the inconvenience.
Back to All FAQs

Do I need an OAT approval to prescribe buprenorphine formulations other than buprenorphine/naloxone for opioid use disorder treatment?

Posted October 14, 2022

No. An OAT approval is not required for prescribing buprenorphine for OAT, irrespective of formulation type.

Other formulations of buprenorphine for OAT include Sublocade®, extended-release buprenorphine injection, and Probphine®, subdermal buprenorphine implant.

While an OAT approval is not required, we expect physicians to to complete certification and training recommended by drug manufacturers for these products. Please refer to the respective product monographs for more information.

Buprenorphine OAT formulations are TPP type 2 drugs, and as such, do not require a TPP form or TPP registration to be prescribed.